S. Tiong Ong

Associate Professor

Duke-NUS Medical School

Singapore

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

S. Tiong Ong is an Associate Professor at Duke-NUS Medical School in Singapore. His research primarily focuses on chronic myeloid leukemia (CML), exploring therapy resistance, disease progression, and the integration of genetic and epigenetic factors in risk assessment. Recent publications include studies on single-cell atlases of primary imatinib resistance and network pharmacology approaches for leukemia differentiation therapy.

Articles (10)

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

S. Tiong Ong

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia

A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify®

Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies

Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers.

THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors

RCA2: a scalable supervised clustering algorithm that reduces batch effects in scRNA-seq data.

SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer

Collaborators (5)

William Ying Khee Hwang

Enrico Petretto

Wee Joo Chng

Xavier Roca

Owen Rackham

Make your next move.